RT Book, Section
A1 Hecht, Keith A.
A1 Liewer, Susanne
A2 Chisholm-Burns, Marie A.
A2 Schwinghammer, Terry L.
A2 Malone, Patrick M.
A2 Kolesar, Jill M.
A2 Bookstaver, P. Brandon
A2 Lee, Kelly C.
SR Print(0)
ID 1187022839
T1 Lymphomas
T2 Pharmacotherapy Principles & Practice, 6e
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781260460278
LK ppp.mhmedical.com/content.aspx?aid=1187022839
RD 2024/10/09
AB LEARNING  OBJECTIVESUpon  completion  of  the  chapter,  the  reader  will  be  able  to:Discuss  the  underlying  pathophysiologic  mechanisms  of  the  lymphomas  and  how  they  relate  to  presenting  symptoms  of  the  disease.Differentiate  the  pathologic  findings  of  Hodgkin  lymphoma  (HL),  follicular  indolent  non-Hodgkin  lymphoma  (NHL),  and  diffuse  aggressive  NHL  and  how  this  information  yields  a  specific  diagnosis.Describe  the  general  staging  criteria  for  the  lymphomas  and  how  it  relates  to  prognosis;  evaluate  the  role  of  the  prognostic  systems  such  as  the  International  Prognostic  Score  for  HL,  the  Follicular  Lymphoma  International  Prognostic  Index  (IPI),  and  the  IPI  for  diffuse,  aggressive  NHL.Compare  and  contrast  the  treatment  algorithms  for  early  and  advanced  stage  disease  for  HL.Assess  the  role  of  autologous  hematopoietic  stem-cell  transplantation  for  relapsed  lymphomas.Delineate  the  clinical  course  of  follicular  indolent  and  diffuse  aggressive  NHL  and  the  implications  for  disease  classification  schemes  and  treatment  goals.Outline  the  general  treatment  approach  to  follicular  indolent  and  diffuse  aggressive  NHL  for  localized  and  advanced  disease.Interpret  the  current  role  for  monoclonal  antibody  therapy  in  NHL.